Influence of Polymorphisms Involved in Platelet Activation and Inflammatory Response on Aspirin-Related Upper Gastrointestinal Bleeding: A Case-Control Study

Narmeen Mallah, Maruxa Zapata-Cachafeiro, Carmelo Aguirre, Eguzkiñe Ibarra-García, Itziar Palacios-Zabalza, Fernando Macías-García, J. Enrique Domínguez-Muñoz, María Piñeiro-Lamas, Luísa Ibáñez, Xavier Vidal, Lourdes Vendrell, Luis Martín-Arias, María Sáinz-Gil, Verónica Velasco-González and Adolfo Figueiras on behalf of the EMPHGEN group

Background: Despite the wide benefits of aspirin and its cost-effectiveness, aspirin prescriptions have been reduced due to idiosyncratic responses in susceptible individuals. Low-dose aspirin and single-nucleotide polymorphisms (SNPs) are independently associated with increased risk of gastrointestinal hemorrhage; however, to-date, no studies investigated the SNP-aspirin interaction effect on upper gastrointestinal hemorrhage (UGIH). Therefore, we aimed to evaluate the role of 25 SNPs in multiple genes involved in platelet activation, angiogenesis and inflammatory response in aspirin-related UGIH.

Methods: A multicenter, full-case–control study was conducted in patients exposed and unexposed to aspirin. Three hundred twenty-six cases diagnosed with UGIH were matched with 748 controls (1:3) by age, gender, health center, and recruitment date. Only adults of European origin were included. Participants were stratified by aspirin exposure and genotype [(Aspirin\(\neg\), wild-type), (Aspirin\(\neg\), wild-type), (Aspirin\(\neg\), genetic variation), (Aspirin\(\neg\), genetic variation)]. For each SNP, the Odds Ratio of UGIH and their 95% confidence intervals were estimated in each subgroup by using the generalized linear mixed models for dependent binomial variables. SNP-aspirin interaction effect was estimated through Relative Excess Risk due to Interaction (RERI) measures.
INTRODUCTION

Aspirin is one of the most commonly used medicines worldwide due to its broad spectrum of health benefits such as analgesic, anti-inflammatory and antiplatelet properties (Thorat and Cuzick, 2015). Some recent studies also suggested that aspirin may have protective effects against cancer; a disease that affects all communities and contributes substantially to the global disease burden by impinging on the lives of tens of millions of individuals each year (Global Burden of Disease Cancer Collaboration, 2019). Moreover, there is extensive evidence about the benefits of aspirin use for the secondary prevention against cardiovascular diseases (Godley and Hernandez-Vila, 2016).

On the other hand, patients on aspirin treatment may manifest idiosyncratic reactions to this drug and may be at risk of bleeding, which consequently limit the widespread use of aspirin as prophylactic of many diseases, despite its effectiveness and low cost (Thorat and Cuzick, 2015). Gastrointestinal bleeding is a frequent clinically relevant adverse effect in patients on low-dose aspirin treatment. Several cohort studies and meta-analyses have demonstrated that low-dose aspirin increases the risk of gastrointestinal bleeding between 37% and 85% (Sutcliffe et al., 2013; Whitlock et al., 2015; Whitlock et al., 2016; Raju et al., 2016; Luo et al., 2019; Haykal et al., 2019).

The idiosyncratic response to aspirin could be related to the genetic susceptibility of the individuals. In fact, genetic variations influence patients’ reactions to drugs (Madian et al., 2012). Likewise, several lines of evidence indicated a possible association between predisposing genetic factors and gastrointestinal disorders (Shiotani et al., 2013; Shiotani et al., 2014; Wu et al., 2016; Cho et al., 2016; Milanowski et al., 2017). For instance, previous studies associated the genetic variant rs689466 with an increased risk of ulcerative colitis and gastric cancer, and rs2238631 with upper gastrointestinal hemorrhage (UGIH) in aspirin users (Zhang et al., 2011; Andersen et al., 2011; Wu et al., 2016).

In specific, it was suggested that single-nucleotide polymorphisms (SNPs) mainly those present in genes involved in drug metabolism, platelet activation and inflammatory response, might increase the risk of gastrointestinal bleeding in users of low-dose aspirin (Shiotani et al., 2010). However, the studies were limited by their small sample size and by the assessment of exposed cases, exclusively (Shiotani et al., 2013; Shiotani et al., 2014; Wu et al., 2016; Cho et al., 2016; Milanowski et al., 2017). The non-inclusion of individuals unexposed to aspirin in the design of these studies made it impossible to assess the direct effect of genetic polymorphisms on gastrointestinal bleeding. Therefore, it could not be ascertained whether the previously reported high risk of bleeding in low-dose aspirin users was a consequence of aspirin consumption, the presence of a genetic variation, or a combination of both factors.

Accordingly, in the current “full” case-control study, we aimed at exploring the association between 25 SNPs in genes involved in platelet activation, angiogenesis and inflammatory response and UGIH in a population of exposed and unexposed cases and controls. In addition, we intended to determine any possible interaction or modification of effect between these SNPs and aspirin intake on the risk of upper gastrointestinal bleeding.

RESULTS

We observed two categories of SNPs that might modify the risk magnitude of UGIH in aspirin consumers. Seven SNPs (rs1387180 A > G, rs2238631 T > C, rs1799964 T > C, rs5050 T > C/T > G, rs689466 T > C, rs1799983 T > A/T > G, and rs7756935 C > A) were “positive modifiers” associated with an excess of risk from aspirin exposure and carrying that genetic variation (1.75 ≤ RERI ≤ 4.95). On the contrary, the following nine SNPs (rs2243086 G > T, rs1131882 G > A, rs4311994 C > T, rs10120688 G > A, rs4251961 T > C, rs3778355 G > C, rs1330344 C > T, rs5275 A > G/A > T, and rs3779647 C > T) were “negative modifiers” and associated with a reduced risk in aspirin users (−2.74 ≤ RERI ≤ −0.95).

CONCLUSION

This preliminary study suggests that polymorphisms in genes involved in platelets activity, angiogenesis and inflammatory response might modify the risk of aspirin-related UGIH. Further studies with larger sample size and in different populations are needed to confirm our findings. If confirmed, this might have great impact on public health, thanks to aspirin’s prophylactic properties in diseases of high incidence and severity.

Keywords: aspirin, upper gastrointestinal haemorrhage, genetic polymorphism, pharmacogenomics, platelet, interaction

METHODS

Study Population and Study Design

A full case-control study that included 326 cases and 748 controls was conducted. The subjects were adults of at least 18 years of age. They were recruited in two time periods (2004–2007 and 2013–2015) from four health centers located in four different Spanish cities: Barcelona, Galdakao, Santiago de Compostela,
and Valladolid. The ethics committee of each involved hospital approved the study protocol and each subject signed a written informed consent before participating in the study.

Cases consisted of hospitalized patients with surgical or endoscopic diagnosis of UGIH. Cases were considered eligible if the diagnosis revealed any of the following ulcers (pyloric, cardia, duodenal, or gastric), erosions (duodenitis pyloric, or cardia), erosive duodenitis, and/or acute gastric mucosal lesions. Hospitalized patients who presented signs of a recent stomach bleeding were also considered as eligible cases, even if the main motive of hospitalization was not UGIH. The signs of recent bleeding were determined according to Forrest classification (Forrest et al., 1974). Cirrhotic patients who did not have variceal esophageal bleeding were included if the endoscopic diagnosis showed any sign of recent bleeding. Patients with endoscopic diagnoses different from those mentioned above were excluded.

Three controls were matched to each case according to their age (+/− 5 years), gender and clinical center. To prevent selection bias due to high aspirin consumption, controls were selected from outpatients or were recruited from the preoperative units among patients who had scheduled non-painful mild surgeries that were not related to aspirin intake. The included surgeries are: prostatic adenoma, prostatic hyperplasia, inguinal or umbilical hernia (strangulated or programmed), eye cataract, phimosis, ear pinning, tubal ligation, plastic surgery, lipoma, vocal cord cyst, septoplasty, varicotomy, thyroid nodules, and thyroglossal cyst (euthyroid). All participants were not biologically related. They were recruited from patients and outpatients of the same health centers in order to ensure that they originate from the same population. Controls that had a history of UGIH or that experienced intrahospital UGIH were excluded. Cases and controls with non-white race were excluded. A detailed list of exclusion and inclusion criteria is available in supplementary data online (see Table S1 of the supplementary materials attached to this article).

Data Collection

A comprehensive questionnaire was designed in a previous study of ours that shares the same protocol (Figueiras et al., 2016). The questionnaire was administered by experienced health personnel who interviewed the subjects. The collected data included: sociodemographic characteristics; smoking, alcohol and caffeine consumption; clinical history; reason for current hospitalization; medicines’ intake; and past episodes of gastric disorders. In addition, cases were asked about the underlying symptomatology, and controls were inquired about the motive of the planned surgery.

Complete pharmacological anamnesis was generated using the following four complementary strategies. First, direct questions were raised to the patients about the name, the daily dose, the indication of use and the source of prescription of the medicines consumed in the past two months, including over-the-counter drugs. Second, information was obtained about the frequent symptoms for which aspirin was prescribed, and the treatments used to reduce these symptoms. Third, prompt cards of the most common commercial aspirin boxes were shown to the participants in order to facilitate the recall process. Fourth, subjects who could not remember a specific information were re-interviewed later during their hospitalization, or were telephoned in case they were discharged before repeating the interview. When a patient was in a poor health condition and could not answer the whole interview, the accompanying persons who were in charge of the patient’s medication (healthcare assistants or direct relatives) were allowed to help him/her complete the interview, however only the information confirmed by the patient was considered. In case the patient had doubts or was not certain about the answers, the given information was confirmed by reviewing the medical records of the patient. Moreover, patients who doubted about the name or the dose of the consumed medicine were telephoned once they discharged from the hospital and requested to check this information in the corner drugstore.

At the end of the interview, the interviewer rated the perceived reliability of each interview by using 0–10 Likert scale. Interviews with a zero score were considered completely unreliable and excluded from the analysis. The scores of the included interviews were then inspected for their influence on the estimated measure of effect as explained later in the statistical analysis section.

An index date of aspirin intake was established in order to ensure that exposure happened prior to any symptom of UGIH. For the cases, the index date was set as the day of occurrence of the first signs or symptoms of UGIH. For the controls, the index date was defined as the interview date. In line with earlier studies, we considered an etiological window of 7 days from the index day. Aspirin intake that occurred after the index date was not considered as exposure in the statistical analysis.

Determination of Helicobacter pylori (H. pylori) Infection

The presence of anti–H. pylori immunoglobulin G was tested in human serum using the Enzyme Linked Immunosorbert Assay (ELISA) commercial kits [Human Anti-Helicobacter pylori IgG ELISA Kit (ab108736, Abcam, Cambridge, England), and Captia™ H. pylori IgG EIA (ref: 2346400, Trinity Biotech Captia, Co. Wicklaw, Ireland)] according to the manufacturer’s protocol. To avoid obtaining any false positive result due to an old infection, patients were asked whether they had been previously treated against H. pylori infection.

Selection of SNPs and Genotyping

An extensive literature review was carried out until April 2017 in order to identify SNPs associated with gastrointestinal disorders, the function of the corresponding genes and the clinical significance of the genetic variation. Subsequently, related SNPs were selected, and samples were genotyped using the iPLEX® Gold chemistry and MassARRAY platform, according to manufacturer’s instructions (Agena Bioscience, San Diego, California).
Statistical Analysis

The participants were stratified according to aspirin exposure [aspirin(+); aspirin(−)] and to genetic profile of each of the 25 SNPs (wild-type; genetic-variation). Accordingly, for each SNP, the patients were grouped into four categories [aspirin(−); wild-type], [aspirin(+); wild-type], [aspirin(−); genetic variation] and [aspirin(+); genetic variation]. The adjusted Odds Ratios (ORs) of UGIH were calculated in each group in comparison with the category [aspirin(−); wild-type]. Subsequently, any potential interaction effect upon the co-presence of genetic polymorphisms and aspirin exposure was explored by estimating the Synergism index (S) (also called effect modification) and the Relative Excess Risk due to Interaction (RERI) along with their 95% CI.

The ORs and their 95% confidence intervals (CI) were estimated using the generalized linear mixed models for dependent binomial variables (González et al., 2014). To build up the statistical models, the following four levels were considered consecutively: study subjects, strata (each case and its three matched controls), recruitment center, and period of patients' enrolment.

A bivariate analysis was carried out to test the effect of the potentially confounding variables. Covariates with a P-value < 0.2 was selected for multivariate logistic regression analysis, while those with higher levels of statistical significance were eliminated successively from the original model, provided that the coefficients of the main exposure variables did not change by more than 10%, and that Schwartz's Bayesian Information Criterion was improved (Schwarz, 1978; Mickey and Greenland, 1989; Bates et al., 2015). The covariates that were retained in the final model are: age, Body Mass Index (BMI), gender, history of artherosclerosis, Helicobacter Pylori infection, gastrointestinal disorders (ulcer or bleeding), source of information (patients or health assistants/direct relatives), number of conducted interviews, answers' reliability score, and exposure to each of the following medicines: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) except aspirin, inhibitors of the proton pump, antiaggregant and anticoagulants. The models were estimated using the lmer function of the lme4 R package (version 1.1-21) (Brown and Prescott, 2006). The analysis was restricted to individuals with complete data on the variables included in the model. The recommendations of Knol M.J., 2012 were followed to represent the interaction between aspirin and each SNP (Knol and VanderWeele, 2012). S was obtained from the ratio of the combined effects to the sum of each of the individual effects of aspirin and polymorphisms. RERI was estimated by contrasting the effects of aspirin exposure and polymorphism together to the sum of each factor considered separately: RERI = OR[(genetic variation; aspirin(+)) − OR [(wild-type; aspirin(+)) − OR[(genetic variation; aspirin(−)) +1 (Hosmer and Lemeshow, 1992; Andersson et al., 2005). The confidence intervals of the interaction terms were calculated by applying the method developed by Figueiras et al. (Figueiras et al., 1998).

RESULTS

Study Population

Of 5,896 interviewed subjects, 326 cases and 748 controls were eligible to be included in the final analysis. The most common exclusion criteria were ineligible endoscopic diagnosis (1,590 cases) and unavailability of biological material (328 cases and 749 controls). The flow diagram of cases and controls enrollment in the study and the reasons of exclusion are presented in supplementary data online (see Figure S1 and Table S1 of the supplementary materials attached to this article). Table 1 summarizes the demographic and clinical characteristics of the study population.

Single-Nucleotide Polymorphisms Genotyping

All the 1,074 biologically unrelated patients were genotyped. High quality of genotyping testing was obtained as revealed by the reproducibility analysis (100%) and genotype recall rate (≥98%). In addition, the controls were in equilibrium with respect to the corresponding SNPs as confirmed by the manual inspection of the clusters’ plots and the HWE analysis (p < 0.001) (see Table S2 of the supplementary materials attached to this article).

Risk Estimation and Interaction Analysis

Aspirin consumption substantially increases the risk of occurrence of UGIH by around six folds [adjusted OR: 5.82 (95% CI: 2.2–10.08)].

Stratifying the analysis by genotype (wild-type vs. genetic variation) and aspirin exposure yielded the following two distinct groups of SNPs. The first group comprises SNPs that increased the risk magnitude of aspirin-related UGIH and was called “positive modifiers”. The second group consists of SNPs that showed protective effect by decreasing the risk value and was named “negative modifiers”.

SNPs as Positive Modifiers of the Effect of Aspirin-Related UGIH

In the absence of aspirin exposure, no association was observed between carrying the following genetic variations and the occurrence of UGIH (rs1387180 A > G, rs2238631 T > C,
TABLE 1 | Description of cases and controls.

| Characteristic | Cases (N = 326) | Controls (N = 748) |
|----------------|----------------|-------------------|
| Age            |                |                   |
| <45            | 41 (12.6%)     | 95 (12.7%)        |
| 45–65          | 117 (35.9%)    | 271 (36.2%)       |
| >65            | 161 (49.4%)    | 370 (49.5%)       |
| missing        | 7 (2.1%)       | 12 (1.6%)         |
| BMI            |                |                   |
| Underweight    | 10 (3.1%)      | 24 (3.2%)         |
| Normal weight  | 114 (35.0%)    | 204 (27.3%)       |
| Overweight     | 128 (39.3%)    | 374 (50.0%)       |
| Obese          | 68 (20.9%)     | 144 (19.3%)       |
| Missing        | 6 (1.8%)       | 2 (0.3%)          |
| Gender         |                |                   |
| Male           | 236 (72.4%)    | 559 (74.7%)       |
| Female         | 87 (26.7%)     | 189 (25.3%)       |
| Missing        | 3 (0.9%)       | 0                 |
| Arthritis      |                |                   |
| No             | 219 (67.2%)    | 469 (62.7%)       |
| Yes            | 86 (26.4%)     | 216 (28.9%)       |
| Missing        | 21 (6.4%)      | 0                 |
| Helicobacter pylori |          |                   |
| No or inconclusive | 27 (8.3%)   | 138 (18.4%)     |
| Yes            | 276 (84.7%)    | 574 (76.7%)       |
| Missing        | 23 (7.1%)      | 36 (4.8%)         |
| Source of information |        |                   |
| Patients       | 259 (79.4%)    | 672 (89.8%)       |
| Healthcare assistants/direct relatives | 67 (20.6%) | 76 (10.2%) |
| Interview Variables |          |                   |
| Number of interviews conducted | 1 | 274 (84.0%) | 644 (86.1%) |
| ≥2             | 52 (16.0%)     | 104 (13.9%)       |
| Reliability of the interview | <5 | 13 (4.0%) | 20 (2.7%) |
| 5–7            | 36 (11.1%)     | 78 (10.4%)        |
| 7–9            | 134 (41.1%)    | 310 (41.4%)       |
| ≥9             | 143 (43.9%)    | 340 (45.5%)       |
| Personal history of gastrointestinal disorders | None or dyspepsia | 208 (63.8%) | 647 (86.5%) |
| Ulcer          | 48 (14.7%)     | 56 (7.5%)         |
| Bleeding       | 70 (21.5%)     | 45 (6.0%)         |
| Exposure to other medications | All Nonsteroidal anti-inflammatory drugs | 131 (40.2%) | 112 (15.0%) |
| (NSAIDs)       | All NSAIDs except aspirin | 111 (34.0%) | 96 (12.8%) |
| NSAIDs metabolized by CYP2C9 | 58 (17.8%) | 37 (4.9%) |
| NSAIDs (M01A group) | 74 (22.7%) | 48 (6.4%) |
| Inhibitors of COX2 | 3 (0.9%) | 6 (0.8%) |
| Nonsteroidal anti-inflammatory agents | 1 (0.3%) | 1 (0.1%) |
| Aspirin and its derivatives | 32 (9.8%) | 19 (2.5%) |
| Analgesics not narcotics | 54 (16.6%) | 56 (7.5%) |
| Inhibitors of the proton pump | 36 (11.0%) | 66 (8.8%) |
| Antiangreggant | 65 (19.9%) | 86 (11.5%) |
| Anticoagulants | 35 (10.7%) | 32 (4.3%) |
| rs1799964 T > C, rs5050 T > G/T > G, rs689466 T > C, rs1799983 T > A/T > G, and rs7756935 C > A | (Table 2) | However, when exposed to aspirin, carriers of the wild-type genotypes of these SNPs are at lower risk of occurrence of UGIH in comparison with carriers of the corresponding genetic variations. The estimated effect on the additive scale of aspirin use by carriers of these genetic variations is larger than the effect of aspirin use by carriers of the wild-type genotypes. This was also revealed by RERI estimations that indicates the presence of positive effect modification of aspirin use across the strata of genotypes (1.75 ≤ RERI ≤ 4.95), though these estimations were not statistically significant (Table 2).

SNPs as Negative Modifiers of the Effect of Aspirin-Related UGIH

Furthermore, carrying any of the following nine SNPs was not associated with the risk of UGIH when the patients were not exposed to aspirin [rs2243086 G > T, rs1131882 G > A, rs4311994 C > T, rs10120688 G > A, rs4251961 T > C, rs3778355 G > C, rs130344 C > T, rs5275 A > G/A > T, and rs3779647(C > T)] (Table 3). However, on the contrary to the pattern of association observed earlier, when exposed to aspirin, carriers of the wild-type genotypes of these SNPs are at higher risk of occurrence of UGIH in comparison with carriers of the corresponding genetic variations.

These findings would indicate that the estimated effect on the additive scale of aspirin use by carriers of these genetic variations is smaller than the effect of aspirin use by carriers of the corresponding wild-type genotypes. The interaction analysis revealed that there is negative effect modification of aspirin use across the strata of genotypes on an additive scale (−2.74 ≤ RERI ≤ −0.95); however, this modification was not statistically significant.

Finally, no modification of effect was observed for the SNP rs2990510 T > G [OR wild-type: 3.98 (95% CI: 1.24–12.76) vs. OR genetic-variation: 4.26 (95% CI: 1.58–11.47); S: 1.19 (95% CI: 0.15–9.42); RERI: 0.51 (95% CI: −5.58, 6.61)]. In addition, no conclusive interpretation could be done about the following 8 SNPs due to the limited number of cases and controls who were aspirin users and carriers of these genetic variations (< 5 subjects in one of the groups): rs2502488, rs1800629, rs361525, rs1143627, rs16944, rs3842787, rs3842788 and rs5788 (see Table S3 of the supplementary materials attached to this article).

DISCUSSION

To our knowledge, this is the first and largest case-control study that assesses the effect of a large number of SNPs in multiple genes involved in platelet aggregation angiogenesis and inflammatory response on the risk of aspirin-related UGIH, and that explores the excess of risk from SNPs-aspirin interaction. We tested the presence of genetic variations at the DNA sequence level, and our preliminary data suggested that variations in these genes might alter the risk magnitude of UGIH in aspirin users. These results are of a high clinical interest as they indicate that the likelihood of occurrence of the idiiosyncratic bleeding response to aspirin depends on the patient’s genotype.
TABLE 2 | Odds ratios (OR) for upper gastrointestinal bleeding associated with aspirin intake and SNPs of the positive modifiers category, and their interaction assessment represented by Synergism Index (S) and Relative Excess Risk due to Interaction (REI).

| Single-Nucleotide Polymorphism (Reference number) | Wild-type genotype | Genetic Variation | OR* (95% CI) for any genetic variation within strata of aspirin intake; p-value | RERI (95% CI) | S (95% CI) |
|--------------------------------------------------|---------------------|-------------------|--------------------------------------------------------------------------------|---------------|-----------|
| rs1387180 A > G                                  |                     |                   |                                                                                  |               |           |
| Aspirin intake (No)                              | 143/358             | 1.00              | 119/278                                                                        | 0.84 (0.60–1.18) | 4.28      | 3.33      |
| Aspirin intake (Yes)                             | 10/12               | 2.99 (1.07–8.37)  | 14/5                                                                           | 7.12 (2.22–22.83) | 3.26      | (0.4–27.59) |
| OR (95% CI) for Aspirin intake within strata of genotype; p-value | 3.19 (1.12–9.08) | P = 0.0293        | 8.74 (2.61–29.24)                                                            | P = 0.0001     | 0.97      | (0.67–1.42) |
| rs2238631 T > C                                 | 74/168              | 1.00              | 188/468                                                                        | 0.97 (0.67–1.41) | 2.22      | 2.08      |
| Aspirin intake (No)                              | 6/5                 | 3.08 (0.69–13.81) | 18/12                                                                         | 5.28 (2.13–13.14) | 1.57      | (0.17–14.97) |
| OR (95% CI) for Aspirin intake within strata of genotype; p-value | 3.78 (0.82–17.43) | P = 0.0881        | 5.44 (2.25–13.17)                                                            | P = 0.0002     | 0.84      | (0.69–55)  |
| rs1799964 T > C                                 | 150/372             | 1.00              | 112/264                                                                        | 1.19 (0.84–1.66) | 1.19      | (0.84–1.66) |
| Aspirin intake (No)                              | 12/10               | 3.73 (1.34–10.40) | 12/7                                                                           | 7.20 (2.38–21.79) | 2.17      | (0.36–12.73) |
| OR (95% CI) for Aspirin intake within strata of genotype; p-value | 3.86 (1.36–10.92) | P = 0.0120        | 7.53 (1.84–17.81)                                                            | P = 0.0026     | 1.94      | (0.6–15.6)  |
| rs5050 T > C/T > G                              | 85/188              | 1.00              | 177/448                                                                        | 0.82 (0.57–1.18) | 0.82      | (0.57–1.18) |
| Aspirin intake (No)                              | 9/8                 | 3.26 (1.03–10.34) | 15/9                                                                           | 4.83 (1.72–13.60) | 1.22      | (0.22–6.90) |
| OR (95% CI) for Aspirin intake within strata of genotype; p-value | 2.75 (0.78–9.73) | P = 0.0444        | 6.05 (2.22–16.53)                                                            | P = 0.0004     | 0.84      | (0.34–23.29) |
| rs689466 T > C                                  | 170/393             | 1.00              | 92/243                                                                         | 0.85 (0.60–1.20) | 0.84      | (0.59–1.20) |
| Aspirin intake (No)                              | 16/12               | 3.42 (1.40–8.36)  | 8/5                                                                           | 8.22 (2.14–31.59) | 2.98      | (0.37–23.96) |
| OR (95% CI) for Aspirin intake within strata of genotype; p-value | 3.72 (1.49–9.26) | P = 0.0090        | 7.88 (2.01–29.36)                                                            | P = 0.0004     | 1.65      | (0.30–55)  |
| rs1799983 T > A/T > G                           | 126/302             | 1.00              | 136/336                                                                        | 1.28 (0.92–1.80) | 1.29      | (0.92–1.81) |
| Aspirin intake (No)                              | 14/10               | 4.01 (1.43–11.20) | 10/7                                                                           | 7.69 (2.49–23.74) | 4.42      | (0.34–49.63) |
| OR (95% CI) for Aspirin intake within strata of genotype; p-value | 4.13 (1.35–12.57) | P = 0.0081        | 4.89 (1.62–14.77)                                                            | P = 0.0048     | 0.12      | (0.01–16.5) |
| rs7756935 C > A                                 | 150/347             | 1.00              | 112/289                                                                        | 1.02 (0.72–1.44) | 1.02      | (0.73–1.44) |
| Aspirin intake (No)                              | 14/9                | 4.02 (1.48–10.93) | 10/8                                                                           | 5.89 (1.90–18.21) | 1.82      | (0.31–10.86) |
| OR (95% CI) for Aspirin intake within strata of genotype; p-value | 3.86 (1.42–10.50) | P = 0.0064        | 6.67 (2.11–21.62)                                                            | P = 0.0013     | 0.74      | (0.5–99)   |

*: Odds Ratio adjusted for: period of patients’ recruitment, previous history of arthrosis, infection with Helicobacter pylori, gastrointestinal disorders (ulcer and bleeding), exposure to NSAIDs except ASA, exposure to inhibitors of the proton pump, exposure to antiaggregant, exposure to anticoagulants, and the interview variables (the number and the reliability of the interview).

Reduction in platelets’ activity, and therefore contribute to increasing the risk of bleeding. Platelets play a fundamental role in homeostasis and platelet rich plasma are suggested to treat specific hemorrhages such as hemorrhagic cystitis (Masieri et al., 2019). In fact, the genetic variant rs1387180 was associated earlier with decreased platelets activity in diabetic patients on aspirin treatment (Postula et al., 2013). Rs689466 belongs to COX-2, a gene involved in the production of prostaglandins which plays a role in platelets aggregation and protects against gastric damage (Caughey et al., 2001). Our findings are in line with previous studies which associated rs689466 with an increased risk of gastrointestinal disorders such as ulcerative colitis and gastric cancer (Andersen et al., 2011; Zhang et al., 2011). We also coincide with Yun Wu who reported that rs2238631 is a risk factor of upper gastrointestinal bleeding in aspirin users (Wu et al., 2016). Nevertheless, our results go beyond that of Wu by showing that aspirin users who are carriers of the wild-type genotype of rs2238631 are not at significant risk of UGIH, and that this genetic variation presents an additional risk of bleeding.
### Table 3

| Single-Nucleotide Polymorphism (Reference number) | Wild-type genotype | Genetic Variation | OR* (95% CI) for any genetic variation within strata of aspirin intake; p-value | REI (95% CI) | S (95% CI) |
|------------------------------------------------|---------------------|-------------------|--------------------------------------------------------------------------------|--------------|-----------|
| rs2243086 G > T | 172/403 | 1.00 | 89/232 | 0.96 (0.67–1.36) | 0.95 (0.67–1.35) | –0.95 | –0.95 | 0.76 | (0.1–5.99) |
| Aspirin intake (No) | 115/305 | 1.00 | 127/331 | 0.94 (0.69–1.32) | 0.95 (0.68–1.32) | –2.76 | 0.49 | 0.95 | (0.1–5.99) |
| Aspirin intake (Yes) | 18/12 | 5.02 (2.01–12.54) | 6/5 | 4.03 (1.07–15.23) | 0.24 (0.03–2.18) | P = 0.7987 | P = 0.0098 | 3.71 (0.94–14.65) | P = 0.0615 |
| OR (95% CI) for Aspirin intake within strata of genotype; p-value | 18/10 | 5.86 (2.26–15.17) | 6/7 | 3.09 (0.87–10.93) | 0.01 (0.00–0.54) | P = 0.7987 | P = 0.0098 | 4.69 (1.19–18.55) | P = 0.0276 |
| rs1131882 G > A | 183/431 | 1.00 | 79/205 | 0.97 (0.68–1.40) | 0.97 (0.67–1.40) | –2.74 | 0.43 | 0.97 (0.67–1.40) | P = 0.8705 |
| Aspirin intake (No) | 119/292 | 1.00 | 129/338 | 1.0 (0.71–1.40) | 1.0 (0.71–1.40) | –1.26 | 0.71 | 1.0 (0.71–1.40) | P = 0.8705 |
| Aspirin intake (Yes) | 10/5 | 6.52 (1.88–22.54) | 14/12 | 3.70 (1.41–9.71) | 0.44 (0.07–2.95) | P = 0.7369 | P = 0.0098 | 4.94 (1.77–13.73) | P = 0.0022 |
| OR (95% CI) for Aspirin intake within strata of genotype; p-value | 13/8 | 6.43 (2.30–18.03) | 11/9 | 4.05 (1.32–12.39) | 0.52 (0.09–2.90) | P = 0.0078 | P = 0.0022 | 3.25 (1.04–10.08) | P = 0.0418 |
| rs3778355 G > C | 133/326 | 1.00 | 129/3100 | 1.0 (0.72–1.40) | 1.01 (0.72–1.40) | –1.26 | 0.71 | 1.0 (0.72–1.40) | P = 0.8705 |
| Aspirin intake (No) | 13/8 | 5.38 (1.85–15.65) | 11/9 | 4.12 (1.41–12.00) | 0.67 (0.11–4.17) | P = 0.0095 | P = 0.0020 | 3.93 (1.35–11.44) | P = 0.0121 |
| Aspirin intake (Yes) | 160/389 | 1.00 | 102/247 | 1.09 (0.78–1.54) | 1.10 (0.78–1.55) | –1.44 | 0.68 | 1.09 (0.78–1.54) | P = 0.8060 |
| OR (95% CI) for Aspirin intake within strata of genotype; p-value | 15/12 | 5.36 (2.13–13.49) | 9/5 | 4.02 (1.11–14.54) | 0.66 (0.13–3.83) | P = 0.0341 | P = 0.0004 | 3.42 (0.90–12.96) | P = 0.6408 |
| rs5275 A > G/A > T | 119/292 | 1.00 | 129/338 | 1.0 (0.71–1.40) | 1.0 (0.71–1.40) | –1.66 | 0.65 | 1.0 (0.71–1.40) | P = 0.9964 |
| Aspirin intake (No) | 7/6 | 5.72 (1.53–21.33) | 15/10 | 4.06 (1.54–10.73) | 0.24 (0.02–2.49) | P = 0.6050 | P = 0.0047 | 4.33 (1.62–11.59) | P = 0.0004 |
| Aspirin intake (Yes) | 129/323 | 1.00 | 133/313 | 1.07 (0.77–1.49) | 1.07 (0.77–1.49) | –1.57 | 0.66 | 1.07 (0.77–1.49) | P = 0.6733 |
| OR (95% CI) for Aspirin intake within strata of genotype; p-value | 13/11 | 5.53 (2.08–14.69) | 11/6 | 4.03 (1.24–13.12) | 0.67 (0.11–4.42) | P = 0.0006 | P = 0.0006 | 6.10 (2.27–16.43) | P = 0.0345 |

* OR: Odds ratio adjusted for: period of patients’ recruitment, previous history of arthrosis, infection with Helicobacter pylori, gastrointestinal disorders (ulcer and bleeding), exposure to NSAIDs except ASA, exposure to inhibitors of the proton pump, exposure to anticoagulants, and the interview variables (the number and the reliability of the interview).
We also detected another group of nine SNPs “negative modifiers” that were found to decrease the risk magnitude of aspirin-related UGIH. As opposed to the “positive modifiers” SNPs, the genetic variants in this category might have a role in enhancing platelet activity which would therefore aid in lowering the odds of occurrence of bleeding. In this regard, an association between rs1131882, rs4311994 and rs3779647 and increased platelet activity in diabetic patients on aspirin therapy has already been reported (Postula et al., 2011; Postula et al., 2013). Studies also indicated that the presence of genetic variations in the COX-2 gene such as rs5275 boosts COX-2 expression and therefore aid in reducing the risk of myocardial infarction and ischemia; cardiac conditions in which platelet activation makes an important contribution (Haybar et al., 2018). rs4251961 was associated with higher expression of fibrinogen that plays a key role in hemostasis, and thus participates in the prevention of bleeding (Wassel et al., 2011). In addition, Postula and colleagues, reported that rs10120688 is associated with decreased platelets activity in aspirin users (Postula et al., 2011). In this study, we also found that aspirin users who are carriers of rs10120688 are at an increased risk of UGIH. However, additionally, we showed that aspirin consumers who are carriers of the wild-type of rs10120688 are at higher risk of developing UGIH than the consumers who are carriers of the genetic variation.

In a similar fashion, previous reports also suggested that rs2243086, rs3778355 and rs1330344 are possible risk factors of gastric mucosal injury induced by aspirin (Wu et al., 2016). In the present study, we also detected that carriers of these genetic variations are at increased odds of developing UGIH, and found that the risk magnitude is even higher in carriers of the wild-type genotypes.

Our study has its strengths and limitations. A main strength of this study is adjusting the measure of effect to factors that were known to increase the risk of gastrointestinal bleeding such as comedication with non-steroidal anti-inflammatory drugs, proton-pump inhibitors, anticoagulants, and previous history of bleeding or peptic ulcer. Memory bias was reduced by demonstrating prompt cards of the most frequent aspirin commercial boxes to the participants. The exclusion of non-white patients also allowed to prevent bias due to racial differences between populations. Moreover, conducting the study in biologically unrelated patients, exclusively, avoided ascertainment bias due to over-representation of SNPs within families (Malomane et al., 2018). Nonetheless, due to the genetic differences between races, our results cannot be generalized to populations that are not Caucasian. Another major limitation of our study is the insufficient sample size. This caused the 95% confidence intervals of RERI and S to be very wide, and consequently the null hypothesis could not be rejected. This occurred despite the fact that we present the largest case-control study. Indeed, low statistical power is a common limitation across candidate gene studies (Salanti et al., 2005; Dumas-Mallet et al., 2017). We therefore consider that our findings should be treated as preliminary ones and they should be further confirmed by (1) other studies with larger sample size before their application in clinical settings; and (2) meta-analysis of other studies about modification effect from aspirin-SNPs interaction on UGIH. Due to the limited sample size, we were not able to determine the dose-response relationship as well as the effect of some SNPs. In addition, we could not analyze the effect of carrying more than one SNP on aspirin-related UGIH due to the limited number of cases and/or controls in some combinations of aspirin exposure and genetic profile (data not shown). In spite of these limitations this study can help designing future pharmacogenomic ones in order to better understand the interaction effect between genetics and aspirin use on UGIH.

In conclusion, our preliminary findings suggest that certain genetic variations might modify the risk magnitude of aspirin-related UGIH. Future studies with larger sample size and additional gene expression analyses are needed to confirm our results and explain the biological effect of these SNPs on aspirin-related UGIH. If confirmed, these findings would have high impact at the clinical and public health levels, because they will permit personalized aspirin prescriptions to prevent diseases with high incidence and mortality rates.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://doi.org/10.6084/m9.ﬁgshare.12030606.v1.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Comité Ético de Investigación Clínica, Área De Salud Valladolid - ESTE (CEIC-VA-ESTE-HCUV; protocol number: PI-14-142) Comité Ético de Investigación Clínica De Galicia (CEIC-G; protocol number: 2013/263), Comité Ético de Investigación Clínica De Euskadi (CEIC-E; protocol number: PI2013101), and Comité Ético de Investigación Clínica De Barcelona (CEIC; protocol number: Es38121226Z). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

CA, LI, XV, and AF conceived the research idea, designed the study and supervised and administered the project. NM did the literature review and conceptualized and wrote the manuscript. NM and MP-L analyzed the data. NM interpreted the data and participated in the genetic laboratory testing. AF supervised the data analysis and interpretation. MZ-C, EI-G, IP-Z, FM-G, JD-M, LV, LM-A, MS-G, and VV-G were involved in patients’
service was carried out at CEGEN-PRB3-ISICIII; Instituto de Salud Carlos III and ERDF (PT17/0019, of the PE I+D+i 2013-2016).

ACKNOWLEDGMENTS

The authors would like to thank the health personnel who helped in recruiting and interviewing the patients.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.00860/full#supplementary-material

REFERENCES

Andersen, V., Nimmo, E., Krasup, H. B., Drummond, H., Christensen, J., Ho, G. T., et al. (2011). Cyclooxygenase-2 (COX-2) polymorphisms and risk of inflammatory bowel disease in a Scottish and Danish case-control study. *Inflammation Bowel Dis.* 17, 937–946. doi: 10.1002/ibd.21440

Andersson, T., Alfredsson, L., Kalberg, H., Zdravkovic, S., and Ahlborn, A. (2005). Calculating measures of biological interaction. *Eur. J. Epidemiol.* 20, 575–579. doi: 10.1007/s10654-005-7835-x

Bates, D., Maechler, M., Bolker, B., and Walker, S. (2015). Fitting Linear Mixed-Effects Models Using lme4. *J. Stat. Software* 67, 1–48. doi: 10.18637/jss.v067.i01

Brown, H., and Prescott, R. (2006). *Applied Mixed Models in Medicine* (Chichester: John Wiley and Sons LTD).

Caughey, G. E., Cleland, I. G., Penglis, P. S., Gamble, J. R., and James, M. J. (2001). Roles of cyclooxygenase (COX)-1 and COX-2 in prostanooid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. *J. Immunol.* 167, 2831–2838. doi: 10.4049/jimmunol.167.5.2831

Cho, J. H., Choi, J. S., Chun, S. W., Lee, S., Han, K. J., and Kim, H. M. (2016). The IL-1B Genetic Polymorphism Is Associated with Aspirin-Induced Peptic Ulcers in a Korean Ethnic Group. *Gut Liver* 10, 362–368. doi: 10.5009/gnl15129

Dumas-Mallet, E., Button, K. S., Boraud, T., Gonon, F., and Munafò, M. R. (2017). Calculating measures of biological interaction. *Eur. J. Epidemiol.* 32, 160254. doi: 10.1007/s10654-016-0108-5

Figueiras, A., Domenech-Massons, J. M., and Cadarso, C. (1999). Regression models: calculating the confidence interval of effects in the presence of interactions. *Stat. Med.* 17, 2099–2105. doi: 10.1002/(sici)1097-0258 (19980930)17:18<2099::aid-sim905>3.0.co;2-6

Figueiras, A., Estany-Gestal, A., Aguirre, C., Ruiz, R., Vidal, X., Carvajal, A., et al. (2016). CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study. *Pharmacogenet. Genomics* 26, 66–73. doi: 10.1097/FCG.0000000000000186

Forrest, J. A., Finlayson, N. D., and Shearman, D. J. (1974). Endoscopy in gastrointestinal bleeding. *Lancet* 2, 394–397. doi: 10.1016/0140-6736(74)91770-X

Global Burden of Disease Cancer Collaboration (2019). Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. *JAMA Oncol.* 5, 1749–1768. doi: 10.1001/jamaoncol.2019.2996

Godley, W. R., and Hernandez-Vila, E. (2016). Aspirin for Primary and Secondary Prevention of Cardiovascular Disease. *Tex Heart Inst. J.* 43, 318–319. doi: 10.14503/THIJ-16-5807

González, J. R., Armengol, L., Guinó, E., Solé, X., and Moreno, V. (2014). SNPassoc: SNPs-based whole genome association studies. *SNPassoc* version 1.9-2 ed, 2014. http://www.creal.cat/jrgonzalez/software.htm [Accessed March 25, 2020].

Haybar, H., Khodadi, E., Zibara, K., and Najmaldin, S. (2018). Platelet Activation Polymorphisms in Ischemic Heart Disease. *Hematol. Drug Targets* 18, 153–161. doi: 10.2174/1871535X18666180326121239

Haykal, T., Barbarawi, M., Zayed, Y., Yelangi, A., Dhillon, H., Goranta, S., et al. (2019). Safety and efficacy of aspirin for primary prevention of cancer: a meta-analysis of randomized controlled trials. *J. Cancer Res. Clin. Oncol.* 145, 1795–1809. doi: 10.1007/s00432-019-02932-0

Hosmer, D. W., and Lemeshow, S. (1996). Confidence interval estimation of interaction. *Epidemiology* 3, 452–456. doi: 10.1097/00001540-199204000-00012

Knol, M. J., and VanderWeele, T. J. (2012). Recommendations for presenting analyses of effect modification and interaction. *Int. J. Epidemiol.* 41, 514–520. doi: 10.1093/ije/dys218

Luo, P. J., Lin, X. H., Lin, C. C., Luo, J. C., Hu, H. Y., Ting, P. H., et al. (2019). Risk factors for upper gastrointestinal bleeding among aspirin users: An old issue with new findings from a population-based cohort study. *J. Formos Med. Assoc.* 118, 939–944. doi: 10.1016/j.jfma.2018.10.007

Madian, A. D., Wheeler, H. E., Jones, R. B., and Dolan, M. E. (2012). Relating human genetic variation to variation in drug responses. *Trends Genet.* 28, 487–495. doi: 10.1016/j.tig.2012.06.008

Malomane, D. K., Reimer, C., Weigend, S., Weigend, A., Sharifi, A. R., and Simianer, H. (2018). Efficiency of different strategies to mitigate ascertainment bias when using SNP panels in diversity studies. *BMC Genomics* 19, 22. doi: 10.1186/s12864-017-4116-9

Masieri, L., Sessa, F., Mari, A., Campi, R., Cito, G., Verrienti, P., et al. (2019). Intravesical application of platelet-rich plasma in patients with persistent haemorrhagic cystitis after hematopoietic stem cell transplantation: a single-centre preliminary experience. *Int. Urol. Nephrol.* 51, 1715–1720. doi: 10.1007/s11255-019-02223-0

Mickey, R. M., and Greenland, S. (1989). The impact of confounder selection criteria on effect estimation. *Am. J. Epidemiol.* 129, 125–137. doi: 10.1093/oxfordjournals.aje.a151501

Milanowski, L., Pordzik, J., Janicki, P. K., Kaplan-Cieslicka, A., Rosiak, M., Peller, M., et al. (2017). New single-nucleotide polymorphisms associated with differences in platelet reactivity and their influence on survival in patients with type 2 diabetes treated with acetylsalicylic acid: an observational study. *Acta Diabetol.* 54, 343–351. doi: 10.1007/s00592-016-0945-y

Postula, M., Kaplan-Cieslicka, A., Rosiak, M., Kondracka, A., Serafin, A., Filipiak, K. J., et al. (2011). Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes. *J. Thromb. Haemost.* 9, 2291–2301. doi: 10.1111/j.1538-7836.2011.04482.x

Postula, M., Janicki, P. K., Rosiak, M., Kaplan-Cieslicka, A., Trzepla, E., Filipiak, K. J., et al. (2013). New single nucleotide polymorphisms associated with differences in platelets reactivity in patients with type 2 diabetes treated with...
acetylsalicylic acid: genome-wide association approach and pooled DNA strategy. *J. Thromb. Thrombolysis* 36, 65–73. doi: 10.1007/s11239-012-0823-6

Raju, N., Sobieraj-Teague, M., Bosch, J., and Eikelboom, J. W. (2016). Updated Meta-Analysis of Aspirin in Primary Prevention of Cardiovascular Disease. *Am. J. Med.* 129, e35–e36. doi: 10.1016/j.amjmed.2015.10.046

Salanti, G., Sanderson, S., and Higgins, J. P. (2005). Obstacles and opportunities in meta-analysis of genetic association studies. *Genet. Med.* 7, 13–20. doi: 10.1097/01.gim.0000151839.12032.1a

Schwarz, G. (1978). Estimating the dimension of a model. *Ann. Stat.* 6, 461–464. doi: 10.1214/aos/1176344136

Shiotani, A., Sakakibara, T., Nomura, M., Yamanaka, Y., Nishi, R., Imamura, H., et al. (2010). Aspirin-induced peptic ulcer and genetic polymorphisms. *J. Gastroenterol. Hepatol.* 25 Suppl 1, S31–S34. doi: 10.1111/j.1440-1746.2009.06212.x

Shiotani, A., Murao, T., Fujita, Y., Fujimura, Y., Sakakibara, T., Nishio, K., et al. (2013). Novel single nucleotide polymorphism markers for low dose aspirin-associated small bowel bleeding. *PloS One* 8, e84244. doi: 10.1371/journal.pone.0084244

Shiotani, A., Murao, T., Fujita, Y., Fujimura, Y., Sakakibara, T., Nishio, K., et al. (2014). Single nucleotide polymorphism markers for low-dose aspirin-associated peptic ulcer and ulcer bleeding. *J. Gastroenterol. Hepatol.* Suppl 4, 47–52. doi: 10.1111/jgh.12770

Sutcliffe, P., Connock, M., Gurung, T., Freeman, K., Johnson, S., Kandala, N. B., et al. (2013). Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. *Health Technol. Assess.* 17, 1–253. doi: 10.3310/hta17430

Thorat, M. A., and Cuzick, J. (2015). Prophylactic Use of Aspirin: Systematic Review of Harms and Approaches to Mitigation in the General Population. *Eur. J. Epidemiol.* 30, 5–18. doi: 10.1007/s10654-014-9971-7

Wassel, C. L., Lange, L. A., Keating, B. J., Taylor, K. C., Johnson, A. D., Palmer, C., et al. (2011). Association of genomic loci from a cardiovascular gene SNP array with fibrinogen levels in European Americans and African-Americans from six cohort studies: the Candidate Gene Association Resource (CARe). *Blood* 117, 268–275. doi: 10.1182/blood-2010-06-289546

Whitlock, E. P., Williams, S. B., Burda, B. U., Feighnter, A., and Beil, T. (2015). Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms. A Systematic Evidence Review for the U.S. Preventive Services Task Force. AHRQ Publication No. 13-05193-ER-1 (Rockville, MD: Agency for Healthcare Research and Quality). Evidence Synthesis No. 132.

Whitlock, E. P., Burda, B. U., Williams, S. B., Guirguis-Blake, J. M., and Evans, C. V. (2016). Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. *Ann. Intern Med.* 164, 826–835. doi: 10.7326/M15-2112

Wu, Y., Hu, Y., You, P., Chi, Y. J., Zhou, J. H., Zhang, Y. Y., et al. (2016). Study of Clinical and Genetic Risk Factors for Aspirin-induced Gastric Mucosal Injury. *Chin. Med. J. (Engl)* 129, 174–180. doi: 10.4103/0366-6999.173480

Zhang, X., Zhong, R., Zhang, Z., Yuan, J., Liu, L., Wang, Y., et al. (2011). Interaction of cyclooxygenase-2 promoter polymorphisms with Helicobacter pylori infection and risk of gastric cancer. *Mol. Carcinog.* 50, 876–883. doi: 10.1002/mc.20784

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Mallah, Zapata-Cachafeiro, Aguirre, Ibarra-García, Palacios-Zabalza, Macías-García, Domínguez-Muñoz, Pérez-Lamas, Ibáñez, Vidal, Vendrell, Martín-Arias, Sánchez-Gil, Velasco-González and Figueiras. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.